The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Centre Hospitalier de l’Université de Montréal · Université de Montréal · +2 more institutions
Abstract
Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign. This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state. Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection-type processes or blocking suppressive pathways. Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor immune responses. In this review, we focus on CD39 and CD73…
Citation impact
- FWCI
- 55.93
- Percentile
- 100%
- References
- 343
Authors
4- BABertrand Allard
Centre Hospitalier de l’Université de Montréal, Université de Montréal
- MSMaria Serena Longhi
Beth Israel Deaconess Medical Center, Harvard University
- SCSimon C. RobsonCorresponding
Beth Israel Deaconess Medical Center, Harvard University
- JSJohn StaggCorresponding
Centre Hospitalier de l’Université de Montréal, Université de Montréal
Topics & keywords
- Immune system
- Adenosinergic
- Immunology
- Cancer
- Purinergic receptor
- Immune checkpoint
- Cancer research
- Cancer immunotherapy
- Good health and well-being